These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 32218808)

  • 61. Targeting STAT3 in Cancer Immunotherapy.
    Zou S; Tong Q; Liu B; Huang W; Tian Y; Fu X
    Mol Cancer; 2020 Sep; 19(1):145. PubMed ID: 32972405
    [TBL] [Abstract][Full Text] [Related]  

  • 62. STAT family of transcription factors in breast cancer: Pathogenesis and therapeutic opportunities and challenges.
    Wong GL; Manore SG; Doheny DL; Lo HW
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):84-106. PubMed ID: 35995341
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Improving Skin Cancer Treatment by Dual Drug Co-Encapsulation into Liposomal Systems-An Integrated Approach towards Anticancer Synergism and Targeted Delivery.
    Corte-Real M; Veiga F; Paiva-Santos AC; Pires PC
    Pharmaceutics; 2024 Sep; 16(9):. PubMed ID: 39339235
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Stat3 Inhibitors TTI-101 and SH5-07 Suppress Bladder Cancer Cell Survival in 3D Tumor Models.
    Singh SP; Pathuri G; Asch AS; Rao CV; Madka V
    Cells; 2024 Aug; 13(17):. PubMed ID: 39273033
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Anticancer Effects of Secoiridoids-A Scoping Review of the Molecular Mechanisms behind the Chemopreventive Effects of the Olive Tree Components Oleocanthal, Oleacein, and Oleuropein.
    Kusuma IY; Habibie H; Bahar MA; Budán F; Csupor D
    Nutrients; 2024 Aug; 16(16):. PubMed ID: 39203892
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation.
    Wang W; Lopez McDonald MC; Hariprasad R; Hamilton T; Frank DA
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611065
    [TBL] [Abstract][Full Text] [Related]  

  • 67. ELTD1 Review: New Regulator of Angiogenesis in Glioma.
    Buzatu I; Tache DE; Manea Carneluti EV; Zlatian O
    Curr Health Sci J; 2023; 49(4):495-502. PubMed ID: 38559823
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A matter of new life and cell death: programmed cell death in the mammalian ovary.
    Chesnokov MS; Mamedova AR; Zhivotovsky B; Kopeina GS
    J Biomed Sci; 2024 Mar; 31(1):31. PubMed ID: 38509545
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics.
    Adesoye T; Tripathy D; Hunt KK; Keyomarsi K
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339245
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Navigating the Cytokine Seas: Targeting Cytokine Signaling Pathways in Cancer Therapy.
    Stanilov N; Velikova T; Stanilova S
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256080
    [TBL] [Abstract][Full Text] [Related]  

  • 71. In silico study of polyphenols as potential inhibitors of MALT1 protein in non-Hodgkin lymphoma.
    Sezer A; Mahmutović L; Akçeşme B
    Med Oncol; 2023 Dec; 41(1):37. PubMed ID: 38155268
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Intradermal Delivery of Naked mRNA Vaccines via Iontophoresis.
    Hasan M; Khatun A; Kogure K
    Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38140019
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Oligonucleotide-Based Therapeutics for STAT3 Targeting in Cancer-Drug Carriers Matter.
    Molenda S; Sikorska A; Florczak A; Lorenc P; Dams-Kozlowska H
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067351
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Selumetinib overcomes gefitinib primary and acquired resistance by regulating MIG6/STAT3 in NSCLC.
    Song X; Wang L; Tang W; Yuan L; Liu Q; Li J; Fan D
    Arch Pharm Res; 2023 Dec; 46(11-12):924-938. PubMed ID: 38032449
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Navigating the Gene Co-Expression Network and Drug Repurposing Opportunities for Brain Disorders Associated with Neurocognitive Impairment.
    Manuel MTA; Tayo LL
    Brain Sci; 2023 Nov; 13(11):. PubMed ID: 38002524
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.
    Taylor PC; Choy E; Baraliakos X; Szekanecz Z; Xavier RM; Isaacs JD; Strengholt S; Parmentier JM; Lippe R; Tanaka Y
    Rheumatology (Oxford); 2024 Feb; 63(2):298-308. PubMed ID: 37624925
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The RNA interactome in the Hallmarks of Cancer.
    Gabryelska MM; Conn SJ
    Wiley Interdiscip Rev RNA; 2023; 14(5):e1786. PubMed ID: 37042179
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Using Single-Cell RNA Sequencing and MicroRNA Targeting Data to Improve Colorectal Cancer Survival Prediction.
    Willems A; Panchy N; Hong T
    Cells; 2023 Jan; 12(2):. PubMed ID: 36672162
    [TBL] [Abstract][Full Text] [Related]  

  • 79. EGFR-Targeted Cellular Delivery of Therapeutic Nucleic Acids Mediated by Boron Clusters.
    Kaniowski D; Suwara J; Ebenryter-Olbińska K; Jakóbik-Kolon A; Nawrot B
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499115
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Role of STAT3 in the pathogenesis of nasopharyngeal carcinoma and its significance in anticancer therapy.
    Si Y; Xu J; Meng L; Wu Y; Qi J
    Front Oncol; 2022; 12():1021179. PubMed ID: 36313702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.